IL299903A - Antibodies against the MUC1-C/EXTRACELLULAR domain (MUC1-C/ECD) - Google Patents

Antibodies against the MUC1-C/EXTRACELLULAR domain (MUC1-C/ECD)

Info

Publication number
IL299903A
IL299903A IL299903A IL29990323A IL299903A IL 299903 A IL299903 A IL 299903A IL 299903 A IL299903 A IL 299903A IL 29990323 A IL29990323 A IL 29990323A IL 299903 A IL299903 A IL 299903A
Authority
IL
Israel
Prior art keywords
muc1
ecd
extracellular domain
antibodies against
antibodies
Prior art date
Application number
IL299903A
Other languages
English (en)
Hebrew (he)
Inventor
Kharbanda Surender
W Kufe Donald
Original Assignee
Dana Farber Cancer Inst Inc
Genus Oncology Llc
Kharbanda Surender
W Kufe Donald
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Genus Oncology Llc, Kharbanda Surender, W Kufe Donald filed Critical Dana Farber Cancer Inst Inc
Publication of IL299903A publication Critical patent/IL299903A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL299903A 2020-07-16 2021-07-15 Antibodies against the MUC1-C/EXTRACELLULAR domain (MUC1-C/ECD) IL299903A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063052599P 2020-07-16 2020-07-16
PCT/US2021/070881 WO2022016190A1 (en) 2020-07-16 2021-07-15 Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)

Publications (1)

Publication Number Publication Date
IL299903A true IL299903A (en) 2023-03-01

Family

ID=79554266

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299903A IL299903A (en) 2020-07-16 2021-07-15 Antibodies against the MUC1-C/EXTRACELLULAR domain (MUC1-C/ECD)

Country Status (11)

Country Link
US (1) US20230265208A1 (enExample)
EP (1) EP4182354A4 (enExample)
JP (1) JP2023534959A (enExample)
KR (1) KR20230116767A (enExample)
CN (1) CN117693530A (enExample)
AU (1) AU2021310499A1 (enExample)
BR (1) BR112023000728A2 (enExample)
CA (1) CA3186181A1 (enExample)
IL (1) IL299903A (enExample)
MX (1) MX2023000784A (enExample)
WO (1) WO2022016190A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202436357A (zh) * 2023-03-03 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Ｍｕｃ１抗體及使用方法
TW202436343A (zh) * 2023-03-03 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Muc1與cd16a抗體以及其使用方法
WO2025217515A2 (en) 2024-04-12 2025-10-16 Dana-Farber Cancer Institute, Inc. Identification of muc1-c as a target for the treatment of squamous cell carcinomas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2601417C (en) * 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
EP3130607B1 (en) * 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1* antibodies
CN106132992B (zh) * 2014-01-29 2020-08-07 达娜-法勃肿瘤研究所公司 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
US10617773B2 (en) * 2016-08-05 2020-04-14 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)

Also Published As

Publication number Publication date
CN117693530A (zh) 2024-03-12
MX2023000784A (es) 2023-04-18
EP4182354A4 (en) 2024-12-25
KR20230116767A (ko) 2023-08-04
JP2023534959A (ja) 2023-08-15
BR112023000728A2 (pt) 2023-03-21
AU2021310499A1 (en) 2023-03-09
CA3186181A1 (en) 2022-01-20
EP4182354A1 (en) 2023-05-24
WO2022016190A1 (en) 2022-01-20
US20230265208A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
IL246997A0 (en) Antibodies against the extracellular domain of (muc1-c (muc1-c/ecd
IL277344A (en) Extracellular vesicles containing agonist-STING
EP3636670A4 (en) ANTI-IGF-I RECEPTOR ANTIBODIES
IL299903A (en) Antibodies against the MUC1-C/EXTRACELLULAR domain (MUC1-C/ECD)
SG11202102688PA (en) Surface modified extracellular vesicles
HUE069963T2 (hu) Kapocsrégióval rendelkezõ notch receptorok
AU201817730S (en) Sunglasses
WO2015009740A3 (en) Anti-mucin 1 binding agents and uses thereof
GB201915855D0 (en) An extracellular vesicle
EP3895732A4 (en) HUMANIZED ANTI-IGF-I RECEPTOR ANTIBODY
GB201901640D0 (en) Antibodies against hepcr
IL280851A (en) Targeted extracellular vesicles
IL262604A (en) Near-end crosstalk cancellation
GB2571098B (en) Hinge for shower doors
EP3626229A4 (en) OIL-IN-WATER EMULSION COMPOSITION
IL308881A (en) Multispecific antibody constructs against THEMUC1-C/extracellular domain (MUC1-C/ECD)
EP4056235A4 (en) OIL-IN-WATER COMPOSITION
SG11202105169WA (en) Transmembrane domain derived from human lrrc24 protein
HK40102189A (zh) 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
HK40106220A (zh) 针对muc1-c/胞外结构域(muc1-c/ecd)的多特异性抗体构建体
EP3934685A4 (en) CD47 EXTRACELLULAR DOMAIN MODIFIED FOR BIOCONJUGATION
GB2579796B (en) Hinges
HK40067288A (en) Engineered cd47 extracellular domain for bioconjugation
GB202108319D0 (en) Single domain antibodies
HK40120556A (zh) C末端抗体变体